Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,647 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,647 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03684967 | Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC | Phase 2 | withdrawn | Sep 26, 2018 | Hutchison Medipharma Limited | the study stopped because the company's strategy. | Sponsor / business decision |
| NCT00205439 | Surveillance For New Lung Primaries | — | terminated | Sep 20, 2005 | University of Wisconsin, Madison | low accrual | Enrollment / accrual |
| NCT01679743 | GRN1005 for Brain Metastases From Breast or Lung Cancer | Phase 2 | withdrawn | Sep 6, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02356991 | A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung… | Phase 2 | suspended | Feb 6, 2015 | Jiangsu HengRui Medicine Co., Ltd. | sponsor decides to suspend this trial | Other (stated, no rule matched) |
| NCT02538432 | Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid… | Phase 2 | withdrawn | Sep 2, 2015 | University of Maryland, Baltimore | PI No Longer at University of Maryland. Now at Fox Chase | Other (stated, no rule matched) |
| NCT03272971 | Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors | N/A | terminated | Sep 6, 2017 | Broncus Medical Inc | Lack of enrollment | Enrollment / accrual |
| NCT02448251 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small… | Phase 1 | terminated | May 19, 2015 | ACEA Therapeutics, Inc. | not stated | Not stated |
| NCT03311672 | T-Cell PET Imaging With [18F]F-AraG in Lung Cancer | Phase 2 | withdrawn | Oct 17, 2017 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced… | Phase 1 / Phase 2 | withdrawn | Jan 8, 2014 | University of Maryland, Baltimore | PI has left the study institution. | Other (stated, no rule matched) |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 24, 2012 | National Cancer Institute (NCI) | Study terminated due to slow/insufficient accrual. | Enrollment / accrual |
| NCT02920450 | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC… | Phase 1 / Phase 2 | terminated | Sep 30, 2016 | University of Florida | Slow accrual | Enrollment / accrual |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | Phase 1 | withdrawn | Jun 11, 2019 | Muhammad Furqan | Sponsor decision to withdraw | Sponsor / business decision |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02002052 | Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized,…(FLAIR) | Phase 2 | terminated | Dec 5, 2013 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Insufficient accrual | Enrollment / accrual |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With… | Phase 1 | terminated | Mar 17, 2016 | Novartis Pharmaceuticals | considering the limited clinical activity observed with LTT462, the decision was made to not open… | Other (stated, no rule matched) |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | N/A | withdrawn | Jan 24, 2018 | University of Southern California | No accrual | Enrollment / accrual |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild…(EGF) | Phase 3 | terminated | Jul 11, 2014 | Bioven Europe | Sponsor decision based on slow recruitment and new emerging drug combinations | Enrollment / accrual |
| NCT02937402 | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune… | N/A | terminated | Oct 18, 2016 | Vanderbilt-Ingram Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Phase 1 / Phase 2 | withdrawn | Jun 9, 2015 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT02132884 | Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV… | N/A | terminated | May 7, 2014 | Fox Chase Cancer Center | Feasibility | Other (stated, no rule matched) |
| NCT03130829 | To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving… | N/A | withdrawn | Apr 27, 2017 | Hi-Q Marine Biotech International, Ltd. | target population is insufficient | Other (stated, no rule matched) |
| NCT03479294 | Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients… | — | terminated | Mar 27, 2018 | West China Hospital | Because of the difficulty of research operation, we changed to another research design. | Other (stated, no rule matched) |
| NCT02054819 | Treating NSCLC Minimal Stage IV With Curative Intent | Phase 2 | terminated | Feb 4, 2014 | Leo W. Jenkins Cancer Center | Didn't meet accrual goal, change in standard of care. | Enrollment / accrual |
| NCT01374100 | Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer… | N/A | terminated | Jun 15, 2011 | McGill University | Slow accrual, and revised power calculation for primary end-points | Enrollment / accrual |
| NCT02200354 | The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab | Phase 2 | terminated | Jul 25, 2014 | Kobe City General Hospital | inclusion speed | Other (stated, no rule matched) |
| NCT02322281 | TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus… | Phase 3 | terminated | Dec 23, 2014 | Clovis Oncology, Inc. | Sponsor discontinued development of CO-1686 for NSCLC | Other (stated, no rule matched) |
| NCT03029871 | Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer(NSCLC) | Phase 1 | withdrawn | Jan 24, 2017 | Benjamin Movsas, M.D. | No participants were enrolled | Enrollment / accrual |
| NCT03785808 | Reducing Insulin, Growth Hormones, and Tumors(RIGHT) | N/A | terminated | Dec 24, 2018 | Fred Hutchinson Cancer Center | Study terminated due to lack of accrual/enrollment | Enrollment / accrual |
| NCT01822496 | Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients… | Phase 2 | terminated | Apr 2, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given… | Phase 2 | terminated | Apr 9, 2014 | Clovis Oncology, Inc. | not stated | Not stated |
| NCT01646125 | An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed… | Phase 2 | terminated | Jul 20, 2012 | Novartis Pharmaceuticals | An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended… | Efficacy / futility |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT02431169 | Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease… | — | terminated | Apr 30, 2015 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | Phase 1 / Phase 2 | terminated | Mar 21, 2016 | PrECOG, LLC. | Company discontinued further development of study drug for this indication | Sponsor / business decision |
| NCT02630186 | A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in… | Phase 1 / Phase 2 | terminated | Dec 15, 2015 | Clovis Oncology, Inc. | The study terminated before Phase 1 was completed. This study was reprioritized within the… | Other (stated, no rule matched) |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI… | N/A | terminated | Dec 9, 2013 | Yale University | Unable to recruit patients. | Enrollment / accrual |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With… | Phase 1 | terminated | Feb 20, 2015 | Millennium Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT00714246 | Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With… | Phase 1 | terminated | Jul 14, 2008 | Milton S. Hershey Medical Center | Low accrual | Enrollment / accrual |
| NCT00685750 | Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma | N/A | terminated | May 28, 2008 | GlaxoSmithKline | Slow enrolment over the last 2 years with none in the past 1 year. No increase in the number of… | Enrollment / accrual |
| NCT03348904 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet… | Phase 3 | terminated | Nov 21, 2017 | Incyte Corporation | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03121417 | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer | Phase 2 | withdrawn | Apr 20, 2017 | Emory University | Slow accrual | Enrollment / accrual |
| NCT02410382 | Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for… | Phase 2 | terminated | Apr 7, 2015 | University of Arizona | IRB suspension, did not resume | Other (stated, no rule matched) |
| NCT02186301 | TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With…(EGFR) | Phase 2 / Phase 3 | terminated | Jul 10, 2014 | Clovis Oncology, Inc. | Sponsor discontinued development of CO-1686 for NSCLC | Other (stated, no rule matched) |
| NCT02080078 | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | Phase 1 | terminated | Mar 6, 2014 | AHS Cancer Control Alberta | REB decision | Other (stated, no rule matched) |
| NCT00568906 | Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung… | — | terminated | Dec 6, 2007 | Stanford University | not stated | Not stated |
| NCT02271906 | The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting | Phase 2 | terminated | Oct 22, 2014 | M.D. Anderson Cancer Center | Poor Accrual | Enrollment / accrual |
| NCT02775006 | Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild… | Phase 3 | terminated | May 17, 2016 | The Netherlands Cancer Institute | accrual to slow, target not achievable | Enrollment / accrual |
| NCT02341170 | HS-PCI in Locally Advanced Adenocarcinoma of the Lung(HIPPO-S) | N/A | withdrawn | Jan 19, 2015 | Universitätsmedizin Mannheim | Lack of Funding | Funding |
| NCT03419559 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in… | Phase 2 | withdrawn | Feb 5, 2018 | Iovance Biotherapeutics, Inc. | The treatment landscape for NSCLC has evolved in the past year. An additional NSCLC arm will be… | Other (stated, no rule matched) |
| NCT00793208 | Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Nov 19, 2008 | Theresa Whiteside, PhD | study closed due to low enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Nov 19, 2019source: clinicaltrials